Table 3.
Antiproliferative Data of Isolated Compounds
| compound | cell linea (IC50
μM)b |
||||
|---|---|---|---|---|---|
| A549 | MDA-MB-231 | MCF-7 | KB | KB-VIN | |
| 1 | 9.4 ± 0.4 | 10 | >10 | 8.0 ± 0.5 | 6.9 ± 0.3 |
| 2 | >10 | >10 | >10 | >10 | 8.4 ± 0.1 |
| 3 | >10 | >10 | >10 | >10 | >10 |
| 4 | 9.1 ± 0.5 | >10 | >10 | >10 | 5.7 ± 0.1 |
| 5 | >10 | >10 | >10 | >10 | >10 |
| 6 | >10 | >10 | >10 | >10 | >10 |
| 7 | >10 | >10 | >10 | >10 | >10 |
| 8 | >10 | >10 | >10 | >10 | >10 |
| 9 | 8.9 ± 0.2 | >10 | 10 | >10 | 6.1 ± 0.5 |
| 10 | 8.2 ± 0.2 | >10 | >10 | >10 | >10 |
| 11 | >10 | >10 | >10 | >10 | >10 |
| PXL (nM)c | 6.3 ± 0.3 | 8.1 ± 0.2 | 11.2 ± 0.3 | 6.8 ± 0.3 | 2786 ± 6.2 |
a
A549 (lung carcinoma), MDA-MB-231 (triple-negative breast cancer), MCF-7 (estrogen receptor-positive and HER2-negative breast cancer), KB, KB-VIN (P-gp-overexpressing MDR subline of KB).
b
Antiproliferative activity expressed as IC50 values for each cell line, the concentration of compound that caused 50% reduction relative to untreated cells determined by the SRB assay.
c
The IC50 data of paclitaxel (PXL) are expressed in nM.